Ovarian Cancer Coverage from Every Angle

Mirvetuximab Soravtansine Plus Bevacizumab in Platinum-Resistant Ovarian Cancer

By: Hillary Ojeda
Posted: Wednesday, July 24, 2019

According to the final results of the phase Ib FORWARD II trial, treatment of mirvetuximab soravtansine with bevacizumab has “favorable tolerability” in patients with platinum-resistant ovarian cancer. David M. O’Malley, MD, of The Ohio State University, and colleagues presented these results at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract 5520).

“The encouraging efficacy compares favorably to reported outcomes for bevacizumab and chemotherapy seen in similar patient populations,” the authors concluded. “These data support continued exploration of the combination in ovarian cancer.”

A total of 66 patients were treated with mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, and bevacizumab. The patients received mirvetuximab soravtansine (6 mg/kg) and bevacizumab (15 mg/kg) on day 1 of a 21-day cycle.

The most prevalent adverse events were diarrhea, nausea, and blurred vision, and they were generally of a low grade. Serious adverse events were generally gastrointestinal issues (with small intestinal obstruction seen in four patients). Objective responses were achieved in 27 patients, for an overall response rate of 41% and a median progression-free survival interval of 7.1 months. However, in a subset analysis of patients who had not received bevacizumab, had one to two prior therapies, and had medium/high FRα levels (defined as at least 50% of cells with at least moderate staining intensity), the overall response rate was 56%, and the median progression-free survival was 9.9 months.

Disclosure: The study authors’ disclosure information may be found at coi.asco.org.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.